Russian biopharmaceutical company Nanolek has registered its quadrivalent human papillomavirus (HPV) vaccine Tsegardex in Armenia. This is the vaccine's first registration outside Russia, the company's press service reported.
“The registration was carried out under the mutual recognition procedure for medicinal products in effect within the Eurasian Economic Union (EAEU),” the statement said.
Tsegardex is the first Russian quadrivalent HPV vaccine intended to prevent diseases caused by virus types 6, 11, 16 and 18. The vaccine was developed by Nanolek in collaboration with the research and production company Combiotech. It entered the Russian market in September 2026.
In Armenia, as in Russia, the vaccine is approved for use in children and adults of both sexes aged 9 to 45.
According to Nanolek CEO Evgeny Barinov, the company is continuing its efforts to register the vaccine in other Eurasian Economic Union markets.
HPV vaccination is included in Armenia's national immunization schedule and has until now been carried out using the U.S.-made quadrivalent vaccine Gardasil. Nanolek's statement does not say whether the Armenian government intends to purchase the Russian vaccine for its national immunization program.
According to information from Armenia's Ministry of Health published by UNICEF, HPV vaccination coverage among girls in the primary target group increased from 8% in 2018 to 34% in 2024, reaching 40% by June 2025. Under the WHO's global strategy, 90% of girls should be fully vaccinated against HPV by age 15 by 2030. The importance of prevention is also underscored by the prevalence of cervical cancer, which ranks second among cancers in women aged 15–44 in Armenia.










